Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease
- 13 October 2011
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 118 (15), 4250-4257
- https://doi.org/10.1182/blood-2011-04-350249
Abstract
Chronic GVHD is one of the most severe complications of allogeneic HSCT. The sclerotic skin manifestations of cGVHD (ScGVHD) result from inflammation and fibrosis of the dermis, subcutaneous tissue, or fascia, leading to significant functional disability. Risk factors and clinical markers associated with ScGVHD remain largely unexamined. By using a single-visit, cross-sectional design, we evaluated 206 patients with cGVHD at the National Institutes of Health. Most patients manifested severe (ie, 63% National Institutes of Health score “severe”), refractory disease (median treatments = 4). ScGVHD was detected in 109 (52.9%) patients. ScGVHD was associated with greater platelet count (P < .001) and C3 (P < .001), and decreased forced vital capacity (P = .013). Total body irradiation (TBI) was associated with development of ScGVHD (P = .002). TBI administered in reduced-intensity conditioning was most strongly associated with ScGVHD (14/15 patients, P < .0001). Patients with ScGVHD had significant impairments of joint range of motion and grip strength (P < .001). Greater body surface area involvement was associated with poorer survival (P = .015). We conclude that TBI, particularly in reduced-intensity regimens, may be an important risk factor for ScGVHD. Widespread skin involvement is associated with significant functional impairment, distressing symptoms, and diminished survival. This trial is registered at http://www.clinicaltrials.gov as NCT00331968.Keywords
This publication has 49 references indexed in Scilit:
- Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteriaBlood, 2011
- Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow TransplantationClinical Cancer Research, 2011
- Sterile inflammation: sensing and reacting to damageNature Reviews Immunology, 2010
- Systemic sclerosis and lupus: Points in an interferon‐mediated continuumArthritis & Rheumatism, 2010
- Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)Bone Marrow Transplantation, 2009
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host diseaseBlood, 2009
- Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With LeukemiaJournal of Clinical Oncology, 2008
- Platelet contributions to the pathogenesis of systemic sclerosisCurrent Opinion in Rheumatology, 2007
- Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: Expanding the sclerodermoid spectrumJournal of the American Academy of Dermatology, 2005
- Sclerodermatous chronic graft-versus-host disease: Analysis of seven casesJournal of the American Academy of Dermatology, 1992